Frontier Biotechnologies

Frontier Biotechnologies Inc., established in 2013, is an innovative biopharmaceutical enterprise based in China with a global outlook and international competitiveness. The company is dedicated to the research, development, production, and sales of innovative drugs addressing significant unmet clinical needs. It has one marketed original new anti-HIV drug that is patented in major global markets, as well as two investigational new drugs in Phase II clinical trials in the United States, which are patented (or licensed) and have demonstrated clear clinical efficacy. Additionally, the company possesses industry-leading capabilities in long-acting peptide drug R&D, an experienced R&D team, GMP-certified manufacturing facilities, a medical promotion team for the Chinese market, and an overseas market development team. Covering the entire industry chain from innovative drug discovery, preclinical R&D, and global clinical development to production and sales, Frontier Biotechnologies holds global competitiveness in the niche sectors of long-acting HIV treatment and immunotherapy.